Clinical trial
Open access
Sep 2026
BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole
BV100 is a mild/weak CYP3A enzyme inducer and a mild substrate for CYP3A inhibitors, however, co-administration with strong CYP3A inhibitors resulted in a disproportionate increase in exposure to the active metabolite 25-O-desacetyl rifabutin, leading to an ∼2-fold increase in total active-moiety exposure.
Pierre Delique, C. Kemmer, Lisa Husband et al.
· Journal of Antimicrobial Che... · 0 citations